Table Of Content

Subject Index .^^ccell® gene delivery system, 282 Clinical trials, European Union and, 180 Adeno-associated virus promoters. Rep CM Vint construct, 128 proteins and, 99 Contamination, primary cell cultures and, 8 Adeno-associated virus-based vectors, 100 Continuous cell lines, 10 Adenovirus Cross clade cytotoxic T cell responses, 189 gene therapy and, 95 Cross-strain protection, 16 recombinant, 236 Crossreactive cytotoxic T lymphocytes, 109 Adenovirus vectors, % Cynomologous monkeys, immune responses Adjuvant role of DNA, 74 in, 190 African green monkeys, rev DNA vaccine Cystic fibrosis transmembrane regulator responses in, 205 (CFTR), 135 AIDS, nucleic acid vaccines against, 182 Cytofectin, 130 Alphavirus, 261 Cytokine Anti-DNA bacterial DNA and, 160 pathogenicity of, 153 ELISPOT assay and, 58 specificity of, 154 Cytokine profiles, DNA-mediated Anti-DNA antibodies, possible induction of, immunization and, 69 166 Cytoplasmic amplification, 263 Anti-viral vaccines, plasmid vectors as, 77 Cytotoxic T lymphocyte Antigen-presenting cells, 69 HIV immunotherapy and, 105 Application, practical, in genetics and intramuscular injection of plasmid DNA vaccinology, 2 and, 42 Autoaggression, long-term expression of nucleoprotein and, 16 foreign antigen and, 1^ SIV and, 210 Autoimmunity, long-term expression of Cytotoxic T lymphocyte activity, pSV3-neo foreign antigen and, 166 induced, 246 Cytotoxic T lymphocyte response exogenous hepatitis B surface antigen and, Bacterial DNA 68 antigenicity of, 155 HIV polynucleotide vaccination and, 198 immunogenicity of, 156 mitogenicity of, 158 Beta-galactosidase intramuscular injection and, 69 Dendritic cells, 71 reporter gene function of, 127 Diagnosis, gB-specific antibodies and, 60 Bupivicaine, reporter gene expression and, 44 (N ,N' ,N'-(Dimethylaminoethane)carbamoyl] cholesterol (DC-cholesterol), 136 advanced melanoma and, 228 Chancer, human, direct gene transfer and, 1.2- Dim yristyloxypropyl-3-dimethylhydroxy- 227 ethyl ammonium bromide (DMRIE), Cationic lipid, 126 136 CD4^ T lymphocytes, protective, 90 advanced melanoma and, 229 CD8" T lymphocytes, protective, 89 Dioleoylphosphatidylethanolamine (DOPE), Cell culture vaccinology, mammalian, 7 129 Cell-mediated immunity, 53 advanced melanoma and, 228 Childhood immunization, DNA vaccines and, 2.3- Dioleyloxy-N-{2-(spermine-carbox- 85 amido)ethyl}-N ,N-dimethyl-1- Chloramphenicol acetyl transferase (CAT), propanaminium (DOSPAX 134 reporter gene fiinction of, 127 N [ 1 -(2,3-Dioley loxy )propy 1 ]-N ,N ,N-trimethy 1 Chromosome ammonium bromide (DOTMA), 136 foreign DNA integration into, 143 Direct gene transfer integration of DNA into, 173 human cancer and, 227 Clinical studies, HIV-seropositive subjects plasmid DNA used for, 21 and, 112 DNA, immunogenicity of, 153 290 ANNALS NEW YORK ACADEMY OF SCIENCES DNA expression vectors, HBV envelope gpl20 DNA protein and, 66 mice and, 201 DNA immunization, many species tested for, monkeys and, 204 51 gpi60/rev DNA, mice and, 203 DNA plasmids, reporter genes and, 15 Guidelines on quality control, 167 DNA vaccination, anti-DNA induction and, 157 DNA vaccine Hayflick’s cell strains, 9 idiotypic, 217 Helper T cell response, HIV polynucleotide naked DNA as, 213 vaccination and, 198 overview of, 15 Hemagglutination inhibition (HI), 119 release of proteins encoded by, 220 Hemagglutinin (HA) DNA, 120 serum antibodies induced by, 218 Hepatitis, chronic, 65 vaginal mucosa and, 265 Hepatitis B surface antigen, 65 DNA vectors, layered amplification of gene Hepatitis B virus expression and, 261 Accell® gene delivery system and, 282 DNA-based immunization, hepatitis B virus DNA-based immunization to, 23 and, 23 DNA-mediated immunization and, 65 DNA-mediated immunization, hepatitis B Herpesvirus gD vaccine, 49 surface antigen and, 64 HIV immunotherapy, retroviral vectors for, 106 HIV polynucleotide vaccination, CTL and Efficacy of DNA vaccines helper T cell responses following, 198 avenues to improve, 82 HIV regulatory genes, nucleic acid initial demonstration of, 16 vaccination with, 278 ELISPOT assay, 58 HIV-1 gpl20, 257 Endotoxin-free DNA production, 272 HIV-1 gpl60 constructs, 188 Eukaryotic genome, natural DNA HIV-serof)ositive subjects, retroviral vector transposition in, 141 immunization and, 111 Eukaryotic layered vector system (ELVS™), Host cell genome, integration into, 30 261 Humoral immune response, naked DNA and, European Agency for the Evaluation of 119 Medicinal Products (EMEA), 181 (-I- / - )-N -(2-Hydroxyethyl)-N ,N-dimethyl-2,3- European Union, marketing authorization in, bis(dodecyloxy)- 1-propanaminium 178 bromide (DLRIE), 135 Exogenous hepatitis B surface antigen, CTL Hyperimmunity, long-term expression of and, 68 foreign antigen and, 166 Exogenous protein, MHC class I presentation and, 74 Idiotypic antigens, lymphoma and, 216 Idiotypic determinants, clonal Ig and, 212 Foreign DNA, risk potential of, 140 Idiotypic protein, CD4^ T cells and, 221 Immune activation, entrainment and, 73 Immune effector mechanisms, response to Clene gun DNA vaccine and, 81 AcceU®, 282 Immune entrainment, amplification of immune SIVmac innoculations and, 209 response and, 71 Gene therapy Immune response direct injection of polynucleotides and, 232 adenovirus and, 237 glycosylated steroids and polyamines and, nature of, 174 268 Immunity, broad-based, 119 human, plasmid DNA and, 271 Immunotherapeutic intervention, DNA- Gene-deleted vaccines, 48 mediated immunization and, 74 Genetic immunization, 17 In vivo challenge system, 189 Glycosteroids, 268 Induced mutation frequency, risk assessment Glycosylation, expression of parasite antigens of, 36 and, 164 Inflammatory environment, 71 SUBJECT INDEX 291 Influenza, increase efficacy of vaccine for, 15 neu/HER-2 cDNA. pregnancy loss and. 274 Influenza A virus, intramuscular injection of Neutralizing antibody, SIV and, 210 plasmid DNA and, 41 Nonhuman primates, immune response Insertion, three ways of, 165 induction in, 110 Insertional mutagenesis, transposable Nonleukocyte cells, immune entrainment and, elements and, 144 73 Integration, host cell genome and, 30 Novel vaccines, 48 Integration of DNA. host chromosome and, Nucleic acid vaccines, 17 173 potential advantages of, 170 Interferon-y, induction of, 159 Nucleoprotein (NP) DNA, 120 Intramuscular injection, hepatitis B surface Nucleoprotein gene, 16 antigen and, 68 Oligonucleotide carrier, 252 Large tumor antigen (T-ag), 241 ompC gene, 286 Life cycle, malaria parasite and, 89 Outer membrane proteins. 285 Lipid emulsion, synthetic oligonucleotide and, 252 Lipofectamine (DOSPA), 134 Packaging cell. HIV immunotherapy and, Lipofection, 126 107 Long-term expression, side effects of, 175 Particle-mediated DNA immunization, 282 Luciferase, reporter gene function of. 127 Passive immunization, efficacy of DNA Lymphoma, recombinant scFv protein and, vaccines and, 83 214 pCDNA3-neuNT, 274 Lymphopoietic tissue, human, HIV and, 281 pCIS-CAT construct, 128 Pigs. HBsAg DNA vaccine and, 282 Plasmid DNA . tuberculosis infection, mouse model of, direct gene transfer and, 21 44 human gene therapy and. 271 Major histocompatibility complex (MHC) Plasmid vectors molecules anti-viral vaccines and, 77 DNA-mediated immunization and, 70 pCIS-CAT and CMVint as, 128 interactions of TCR with, 15 Plasmodium infection, nucleic acid malaria Major histocompatibility complex (MHC) vaccines and, 88 proteins, fresh tumors and. 227 Plasmodium voelii circumsporozoite protein Mammalian cell substrates, development and (PyCSP), 89 acceptance of, 7 Plasmodium yoelii hepatic/erythrocytic Marketing authorization. European Union protein 17 (PyHEP17). 90 and, 178 pM160-Z6 immune monkey serum, anti-viral Maternal transfer of antibodies, efficacy of activity of, 191 DNA vaccines and, 83 Polymerase chain reaction (PCR). purified Mice host genomic DNA and. 31 gpl20 DNA-mediated antibody responses Polynucleotide expression vectors. 17 in. 201 Polynucleotide vaccines, 17 gpl60/rev DNA vaccine responses in, 203 Preclinical development, European Union HBsAg DNA vaccine and, 282 and, 180 rev DNA vaccine responses in, 205 Preerythrocytic stage antibodies, 90 Monkeys, HBsAg DNA vaccine and, 282 Pregnancy loss. neu/HER-2 cDNA and, 274 Protection. SIV and, 210 Protein expression, duration of, 73 Naked DNA, 18 Protooncogenes, activation of, 147 immunization against viral proteins with. pSV3-neo induced humoral immunity, 245 117 Purification, host genomic DNA and, 30 intramuscular immunization with, 40 layered vector system and, 261 S. typhi ompC gene and, 285 ^^lAGEN procedure, 272 Natural DNA transposition, eukaryotic Quality, plasmid DNA and. 271 genome and, 141 Quality control, guidelines for, 167 292 ANNALS NEW YORK ACADEMY OF SCIENCES Skeletal muscle, plasmid DNA in, 22 bbit papilloma virus, 41 Subunit vaccines, 48 Rabies virus G protein, DNA vaccines Systemic lupus erythematosus (SLE), expressing, 80 serology oE 152 Regenerating muscle, gene transfer in, 23 Regulatory issues DNA vectors and, 6 TT cell response use of DNA vaccines and, 170 DNA-mediated immunization and, 65 Regulatory perspectives, 18 naked DNA and, 121 Rep proteins, adeno-associated virus and, 99 Thl cytokines, 70 Reporter gene, luciferase as, 127 Therapeutic vaccination, DNA-mediated Responders, poor, 65 immunization and, 64 Retroviral vector, HIV immunotherapy and, Tolerance, long-term expression of foreign 105 antigen and, 166 Rev DNA Transduced cells, HIV immunotherapy and, African green monkeys and, 205 106 mice and, 205 Transfection Rhesus monkeys, gpI20 DNA vaccine cationic lipid-mediated, 126 responses in, 204 glycosteroid-polyamine compounds and, Risk assessment, host genomic DNA and, 36 268 Risk potential, foreign DNA and, 140 Transfection of muscle fibers, 72 RNA vaccination, 255 Transformational event, extraneous DNA RNA vaccines, 18 and, 165 Tumor suppressor genes, inactivation of, 147 Safety DNA vectors and, 1 IJneo-NP plasmid, PCR amplification integration into genome and, 30 and, 32 mammalian cell cultures and, 8 Vaccine vector, adenovirus as, 97 Saline injections, 209 Vaginal mucosa, 265 Salmonella typhi, 285 Vector localization, HIV immunotherapy and, SemUki Forest virus (SFV)-RNA, 255 109 Severe combined immunodeficiency (SCID) Vector vaccines, ultimate simplicity in, 4 mice, HIV regulatory genes and, 281 Vectors, DNA, safety and, 1 Simian immunodeficiency virus, HlV-2 and, Viral DNA integration, specific site of, 98 186 Viral proteins, naked DNA and, 117 Simian immunodeficiency virus macaque Viral vectorology, DNA vectorology and, 3 (SlVmac), 209 Virally induced tumors, nucleic acid Simian virus 40 (SV40), large tumor antigen vaccination against, 241 of, 241 Single chain Fv (scFv) sequences, 215 Site, specific, of viral DNA integration, 98 Wo« Health Organization Biologicals Site-specific integration, targeting and Unit, 168 tethering, 149 World Wide Web, 64 Index of Contributors .^k.gadjanian. M., 186-197 Ertl, H. C. J., 77-87 Amici, A., 274-277 Anderson, D. J., 265-267 Feigner. P. L., 126-139, 227-231 Arthos, J., 209-211 Francotte, M., 255-256 Ashworth, L. J., 212-226 Freed. D. C., 198-208 Axelrod, H., 268-270 Fuller. D. H., 282-284 Fuller, J. T., 282-284 ^Babiuk, L. A., 47-63 Babu, S., 268-270 Galpin, J., 105-116 Baca-Estrada, M., 47-63 Gilbert. L., 186-197 Banks, T. A., 261-264 Giraud, C., 95-104 Belli, B. A., 261-264 Gonzalez, C. R., 285-288 Berns, K. 1., 95-104 Gordon, D., 227-231 Bishop, K., 227-231 Gowda, K., 88-94 Borrebaeck, C. A. K., 278-281 Gramzinski, R., 88-94 Boyer, J., 186-197 Griffiths, E., 164-169 Bravo, L. M., 252-254 Bright, R. K., 241-251 Halpem, M. D., 152-163 Bruck, C., 255-256 Haubrich, R., 105-116 Brumm, D., 261-264 Hawkins, R. E., 212-226 Bydlowski, S. P., 252-254 Haynes, J. R., 209-211, 282-284 He, Z., 77-87 Hedstrom, R. C., 88-94 C<ambridge, G., 257-260 Hilleman, M. R., xi-xiv, 1-14 Carrano, R., 186-197 Hinkula, J., 278-281 Chada, S., 261-264 Hobart, P., 88-94 Chang, A. E., 227-231 Hoffman, S. L., 88-94 Chang, S. M. W., 261-264 Cheng, S. H., 126-139 Isibasi, A., 285-288 Cichutek, K., 178-185 Cohen, J., 255-256 Concetti, A., 274-277 Johnson, E., 209-211 Coney, L., 186-197 Jolly. D. J., 105-116, 261-264 Cox, G., 47-63 Crowley, S. D., 152-163 Kakarla, R., 268-270 Kass-Eisler, A., 232-240 Dalemans, W., 255-256 Kennedy, R. C., 241-251 Dang, K., 186-197 King, C. A., 212-226 Davies, M-E., 198-208 Klonisch, T., 257-260 Davis, H. L., 21-29, 64-76 Kogan, N., 268-270 de Souza, B., 257-260 Kumar, S., 212-226 Debes, A. A., 252-254 Kurth, R., xi-xiv, 140-151 Deck, R. R., 117-125 Delers, A., 255-256 Latham, E. M., 261-264 Delmelle, C., 255-256 Leclerc, C., 64-76 Delves, P. J., 257-260 Ledwith, B. J., 30-39 Denamur, F., 255-256 Leinwand, L. A., 232-240 Deriaud, E., 64-76 Letvin, N. L., 209-211 DeWitt, C. M., 117-125 Lewis, P. J., 47-63 Donnelly, J. J., 40-46, 117-125 Li, K.. 232-240 Doolan, D. L., 88-94 Liu, M. A., xi-xiv, 15-20, 40-46, Driver, D. A., 261-264 117-125, 198-208 Dubensky, T. W., Jr., 261-264 Livingston, J. B., 265-267 293 294 ANNALS NEW YORK ACADEMY OF SCIENCES Longley, C., 268-270 Schwartz, S., 278-281 Lopez-Hernandez, M. A., 285-288 Seddon, T.. 271-273 Lopez-Maci'as, C., 285-288 Sedegah, M., 88-94 Lu, S., 209-211, 265-267 Shearer, M. H.. 241-251 Lund. T., 257-260 Shiver, J. W., 198-208 Sofia, M., 268-270 M, lanam, S. V., 30-39 Srikantan, V., 186-197 Manson, K., 209-211 Stable. E. L., 278-281 Manthorpe, M., 126-139 Stevenson, F. K., 212-226 Maranhao, R. C., 252-254 Sukhu, L., 126-139 Margalith, M., 88-94 Marquet, M., 227-231 Xhiriart, C., 255-256 Marshall, J., 126-139 Thompsett, A., 212-226 Matear, P., 257-260 Tikoo, S. K., 47-63 McCabe, D., 282-284 Troilo, P. J., 30-39 McCallus, D., 186-197 Tsai. Y. J., 126-139 Mento, S. J., 105-116, 261-264 u Merritt, J., 105-116 Igen, K., 186-197 Merva, M., 186-197 Ulmer, J. B., 40-46, 117-125 Meykens, R.. 255-256 Michel, M-L., 21-29 an Drunen Littel-van den Hurk, S. Midha, S., 268-270 47-63 Minor, P. D., 170-177 Veenstra, S., 255-256 Moelling, K., 186-197 Venanzi, F. M., 274-277 Montefiori, D., 209-211 Verma, P., 77-87 Moritz, P., 271-273 Vinagre, C. G., 252-254 Mullins, J. 1., 209-211 Vyakamam, A., 257-260 Mustafa, F., 209-211 N. Waa hren, B.. 278-281 label, E. G., 227-231 Walker, S., 268-270 Nabel, G. J., 227-231 Wang, B., 186-197 Nichols, W. W., 30-39 Wang, H., 88-94 Norman, J., 88-94 Warner, J. F., 105-116 O Weiner, D. B., 186-197 rtiz-Navarrete, V., 285-288 Whalen, R. G., 21-29, 64-76 Wheeler, C. J., 126-139 i eet, N., 257-260 Widera, G., 282-284 Perry, H. C., 198-208 Wierichs, L., 268-270 Petrelli, C., 274-277 Wigzell, H.. 278-281 Pisetsky, D. S., 152-163 Wilkinson, L., 257-260 Polo, J. M., 261-264 Williams, W. V., 186-197 Winsink, J., 209-211 R. Wyand, M., 209-211 k.eich, C., 152-163 Reimann, J., 64-76 Robinson, H. L., 209-211, 265-267 Xiang, Z. Q., 77-87 Yang, Z-Y., 227-231 Santoro, J. C., 209-211 Yasutomi, Y., 209-211 Schirmbeck, R., 64-76 Schleef, M., 271-273 Schorr, J., 271-273 Zhu, D., 212-226